10 th International Symposium. GvH/GvL 2012



Similar documents
Dear colleagues and friends,

Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients

The EBMT Cellular Therapy and Immunobiology Symposium

Challenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose

Program Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center

16 TH -17 TH INNOVATIONS IN ONCOLOGY NOVEMBER HEIDELBERG

Workshop on Oral cgvhd & Clinical practice in cgvhd

5th International Advanced ICAS Training Course on "Blood Stem Cell Transplantation: State of the Arts, Methods and Perspectives" June 2009

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris

The donor search: the best donor or cord blood unit

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Summer School 2011 Berlin SFB Transregio 19

A fact sheet UNRELATED BONE MARROW AND CORD BLOOD STEM CELL TRANSPLANTS

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION

Keeping you in touch with our CordBank community

Severe Combined Immune Deficiency (SCID)

storage and handling of unused stem cell products Swiss consensus?

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR

Cord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program

Bone Marrow/Stem Cell Transplant

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Stammzelltransplantation. Neues vom immunologischen Ctrl-Alt-Del

On April 4, a group of physicians at the 37th annual

Corporate Medical Policy Cord Blood as a Source of Stem Cells

BONE MARROW FAILURE DISEASE SYMPOSIUM SATURDAY SEPTEMBER 27, 2014 AN UPDATE ON THE LATEST IN DIAGNOSIS AND TREATMENT

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

MEDICAL SCIENCES SPRING SCHOOL. International Research Training Group 1874/1 Diabetic Microvascular Complications

Phone: Fax:

CPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD

FOCUS ON BIOLOGICAL THERAPIES IN HEMATOLOGIC MALIGNANCIES

Corporate Medical Policy

Corporate Medical Policy

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

Umbilical Cord Blood Transplantation

What we will discuss today

GVHD pathology - A Review

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

15350 Sherman Way, Suite 350 Van Nuys, CA Phone Fax April 17, 2015.

Program Application for CME credits submitted

Disclosures. I have no disclosures.

Stem Cell Transplantation

UMBILICAL CORD BANKING. (formerly Unistem Biosciences Pvt.Ltd.)

Corporate Medical Policy Cord Blood as a Source of Stem Cells

SAVE A LIFE... BY GIVING LIFE!

7 th SSHO Invitation to the. 7 th Swiss Summit on Hemato-Oncology

Genomics in Hematology

UMBILICAL CORD BLOOD, STEM CELL BANKING

OUR JOURNEY THROUGH THE YEARS

5 th Heidelberg Myeloma Workshop

It s not something you want to think about, but it s something you want to prepare for.

Top Ten Things to Know About Stem Cell Treatments

Umbilical Cord Blood Stem Cells Current Status & Future Potential

Graft Versus Host Disease Symposium and Canadian Blood Services Symposium

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD

OVERVIEW OF CURRENT STATUS OF STEM CELL TRANSPLANTATION IN VIETNAM

Cord Blood Stem Cell Transplantation

Search Coordinator Certificate

What is a Stem Cell Transplantation?

Midwinter Conference 2015 January Seefeld, Tyrol CONFERENCE PROGRAM. midwinter2015.org. Sponsored by

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

cord blood saves lives...

Allogeneic stem cell transplant in HIV-1-infected individuals

MEDICAL COVERAGE POLICY

30th GMS. Russisches Haus der Wissenschaft und Kultur Friedrichstraße Berlin-Mitte

Blood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide

Stem Cell Transplantation In Patients with Fanconi Anemia

Graft-versus-host disease (GvHD)

Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. April Reference: NHSCB/B04/P/a

IPMSC First Scientific Conference Daily Program

Understanding How Existing and Emerging MS Therapies Work

Stem cells from Cord Blood: Myths, reality and potential. Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute

Bio Deutschland CEO & CFO-Meeting 29. November Unternehmertum in den Life Sciences am Beispiel der Geschichte von Miltenyi Biotec

Die Periphere Blutstammzell- Transplantation

How do plasma cells survive

STEM CELL FELLOWSHIP

The Infinite Potential of Stem Cell Japan s Cord Blood Bank and Transplant

Blood and Marrow Stem Cell Transplantation

House Resolution No. 37

T u m o r D o r m a n c y

How To Treat Cord Blood

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Saving Cord Tissue for Your Family

Transcription:

10 th International Symposium GvH/GvL 2012 Thon Dittmer Palais, Regensburg, Germany March 28 to 30, 2012

Organized by Ernst Holler Reinhard Andreesen Hans Jochem Kolb Selim Corbacioglu Marina Kreutz Petra Hoffmann Matthias Edinger Daniel Wolff Supported by

Dear colleagues, The biggest challenge in transplantation medicine is to understand and manage the immunology of graft versus host and graft versus leukemia reactions. The GvH/GvL meeting was first organized by Hans Jochem Kolb in 1995 and it has since been a tradition of this meeting held every two years that the latest achievements are monitored, discussed and put yet another step forward. It is a great pleasure and honour for us to continue a meeting series so well renowned and rich in tradition and host it in the historical walls of Regensburg. Enormous progress was made in elucidating the mechanisms of GvH and GvL and improving the management of our patients. Today we seem to be closer to having the tools to specifically shape the immune repertoire in the context of GvL and DLI. Restoring immune regulation in gastrointestinal GvHD, the central role of the inflammasome and APCs, targets like the hematopoetic niche or B cell reconstitution and an update on the use of donor lymphocytes and the clinical relevance of SNPs to predict GvHD and outcome are the major topics of this year s meeting. For the first time, the Hans Jochem Kolb research award will be granted to young and enthusiastic scientists. As in the previous meetings we aim to have two days of intensive interaction to discuss and develop up to date concepts within a small group of invited speakers, chairs and discussants. The Thon Dittmer Palais is situated in the historical centre of the city and allows us to come together not only for presentations, but also for interactive evening discussions. We are looking forward to welcoming you in Regensburg in March 2012! Yours sincerely Prof. Dr. Ernst Holler Prof. Dr. Reinhard Andreesen

Program Wednesday, March 28 12.30 13.00 Welcome Lunch 13.00 13.15 Welcome 13.15 16.30 Targets of GvH and GvL: Chairs: Daniel Wolff, Nicolaus Kröger The hematopoietic niche 3D model systems of the hematopoietic stem cell niche Peter Wuchter, Heidelberg The hematopoietic niche possible target in GvH and GvL Jochen Grassinger, Regensburg GvH and GvL in myelofibrosis graft versus hematopoietic niche? Nicolaus Kröger, Hamburg B cells B cell deficiencies in autoimmune diseases and splenic disorders Rita Carsetti, Rome B cells in cgvhd Hildegard Greinix, Vienna B cell deficiency and GvHD role of the bone marrow B cell niche Matthias Edinger, Regensburg 16.30 17.00 Coffee Break

17.00 18.30 The Inflammasome Chairs: Marina Kreutz, Andreas Mackensen The inflammasome from sensing danger to inflammatory disease Lars French, Zürich Mechanisms of RIG I induced inflammasome activation and antitumor immunity Hendrik Poeck, München NALP3 inflammasome and GvHD Robert Zeiser, Freiburg 19.00 21.00 Open Plenary Discussion (with beer and brezl) Steroid resistant GvH: Mechanisms and trends

Thursday, March 29 8.30 10.30 Intestinal Inflammation Chairs: Matthias Stelljes, Lutz Uharek Lessons from IBD Gerhard Rogler, Zürich Vit D in intestinal inflammation Margerita Contorna, Pennsylvania Intestinal flora and induction of regulatory T Cells Markus Geuking, Bern The role of epithelial regeneration and the microbiome in GvHD Marcel van den Brink, New York IL32 and epithelial protection Joachim Deeg, Seattle TLRs and intestinal GvHD Axel Nogai, Berlin 10.30 11.00 Coffee Break 11.00 13.30 Predictors of Outcome in 2012: SNPs and Proteomics Chairs: James LM Ferrara, Selim Corbacioglu The Seattle view John Hansen, Seattle NOD2 in 2012 Walter van der Velden, Njimwegen The European scores Anne M. Dickinson, Newcastle

Reg3 a as a biomarker of intestinal GvHD James LM Ferrara Proteomics to predict steroid resistant GvHD Eva Maria Weissinger, Hannover 13.30 14.30 Lunch 14.30 17.00 GvL in 2012 Chairs: Dietger Niederwieser, Wolfgang Herr GvL and Cord Blood Hans Jochem Kolb, München Minor antigen specific strategies Fred Falkenburg, Leyden Leukemia antigen specific strategies Martin Bornhäuser, Dresden a/ß T cell depletion and GvL by gamma/delta T cells Rupert Handgretinger, Tübingen GvL in daily clinical practice Jürgen Finke, Freiburg 17.00 18.00 Short presentation of abstracts 19.00 Hans Jochem Kolb Award

Friday, March 30 08.30 11.00 Activation of APCs Chairs: Hermann Einsele, Petra Hoffmann Inflammatory checkpoints Ron Chakraverty, London Priming of T cells Andreas Beilhack, Würzburg Role of LCs in GvHD Ralf Meyer, Mainz Cross presentation in GvHD Matthew Collin, Newcastle CMV Replication after Allogeneic Stem Cell Transplantation Is associated with a reduced Relapse Risk in AML: Evidence For a Putative Virus Versus Leukemia Effect Ahmet Elmaagacli, Essen Vit D and GvHD Marina Kreutz, Regensburg 11.00 11.30 Coffee Break 11.30 13.00 IDO and Peripheral Tolerance Chairs: Edward Geissler, Anne Janin 13.00 13.15 Summing up IDO and IFNgamma in solid organ and stem cell transplantation Andreas Heitger, Vienna IDO producing cells in the gut Anne Janin, Paris Tryptophan metabolites in GvH and GvL Ernst Holler, Regensburg

This symposium would not have been possible without the generous support with unrestricted educational grants from: Amgen GmbH Alexion Pharma Germany GmbH Bristol Myers Squibb GmbH & Co. KGaA Celgene GmbH Fresenius Biotech GmbH Gilead Sciences GmbH Johnson & Johnson Medical GmbH, Geschäftsbereich Therakos Medac GmbH MSD Sharp & Dohme GmbH Miltenyi Biotec GmbH Novartis Pharma GmbH Roche Pharma GmbH

Conference Venue Thon Dittmer Palais Haidplatz 8 93047 Regensburg Germany General tourist and hotel information Tourist Information Altes Rathaus Rathausplatz 4 93047 Regensburg Germany Tel.: +49 (0)941/507 4410 Tel.: +49 (0)941/507 4411 http://www.tourismus.regensburg.de/tourismus/de/medienportal/1160 Local Contact Susanna Blüml Dept. of Hematology and Oncology University of Regensburg F.J. Strauss Allee 11, 93053 Regensburg, Germany Tel.: +49 941 944 5542 Fax: +49 941 944 5543 susanna.blueml@klinik.uni regensburg.de